TransMedics Group (NASDAQ:TMDX) Stock Rating Reaffirmed by Piper Sandler

Piper Sandler reissued their overweight rating on shares of TransMedics Group (NASDAQ:TMDX) in a research report released on Wednesday, Benzinga reports. Piper Sandler currently has a $120.00 price target on the stock, up from their previous price target of $95.00.

TMDX has been the subject of several other research reports. Morgan Stanley increased their price target on TransMedics Group from $75.00 to $95.00 and gave the company an equal weight rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. lifted their price objective on TransMedics Group from $87.00 to $105.00 and gave the stock an overweight rating in a research report on Tuesday, February 27th. Finally, Oppenheimer upped their target price on TransMedics Group from $105.00 to $125.00 and gave the company an outperform rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, TransMedics Group has an average rating of Moderate Buy and an average target price of $119.00.

TransMedics Group Price Performance

TransMedics Group stock opened at $117.60 on Wednesday. The stock has a 50-day moving average price of $83.85 and a two-hundred day moving average price of $75.92. TransMedics Group has a 12 month low of $36.42 and a 12 month high of $124.18. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The business had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. During the same quarter last year, the business earned ($0.08) EPS. The firm’s quarterly revenue was up 132.9% on a year-over-year basis. On average, equities research analysts expect that TransMedics Group will post -0.14 EPS for the current year.

Insider Activity

In other news, CEO Waleed H. Hassanein sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the transaction, the chief executive officer now owns 74,087 shares in the company, valued at $7,044,932.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other TransMedics Group news, CEO Waleed H. Hassanein sold 4,000 shares of TransMedics Group stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total transaction of $380,480.00. Following the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at approximately $7,047,155.44. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Waleed H. Hassanein sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at $7,044,932.83. The disclosure for this sale can be found here. Insiders sold 102,078 shares of company stock worth $8,691,221 over the last three months. 7.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Venturi Wealth Management LLC bought a new stake in shares of TransMedics Group during the 1st quarter worth $30,000. Cutler Group LLC CA increased its holdings in TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after buying an additional 600 shares during the last quarter. First Horizon Advisors Inc. raised its position in TransMedics Group by 26.8% in the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after acquiring an additional 222 shares during the period. RiverPark Advisors LLC purchased a new position in TransMedics Group in the third quarter valued at about $60,000. Finally, Van ECK Associates Corp lifted its stake in TransMedics Group by 39.0% in the third quarter. Van ECK Associates Corp now owns 2,127 shares of the company’s stock valued at $116,000 after purchasing an additional 597 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.